Physician profile
Donald E Hauser
NPI 1316990674
$107,991.36
in general payments reported to CMS, 2019-2025
37 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,158 · 2021: $3,819 · 2022: $2,853 · 2023: $18K · 2024: $45K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Honoraria: $16K · Food and Beverage: $12K · Travel and Lodging: $2,341 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,000.00 |
| Honoraria | $15,675.00 |
| Food and Beverage | $12,379.35 |
| Travel and Lodging | $2,341.17 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $74,361.32 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $15,487.62 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $2,229.42 | 2019-2025 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,102.61 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,685.26 | 2019-2025 | Rexulti |
| Abbvie INC. | $1,580.56 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,569.18 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $1,393.37 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Neurocrine Biosciences, INC. | $1,295.91 | 2019-2025 | Ingrezza |
| Corium, LLC | $844.22 | 2021-2025 | Azstarys, Adlarity |
| Teva Pharmaceuticals USA, INC. | $815.42 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $779.42 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $761.30 | 2019-2025 | Fanapt |
| Allergan, INC. | $289.16 | 2019-2020 | |
| Neos Therapeutics, Lp | $273.80 | 2019-2025 | Adzenys Xr-Odt |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $256.45 | 2019-2025 | Dyanavel Xr |
| Eisai INC. | $237.51 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $234.04 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $234.00 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $206.95 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $176.35 | 2021-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $172.23 | 2019 | |
| Merck Sharp & Dohme LLC | $152.04 | 2020-2023 | Belsomra |
| Noven Therapeutics, LLC | $151.77 | 2020-2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $135.21 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $132.96 | 2019-2021 | |
| Almatica Pharma LLC | $89.76 | 2021-2023 | Loreev Xr |
| Indivior INC. | $67.54 | 2022-2023 | Sublocade |
| Adlon Therapeutics L.P. | $60.78 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $54.32 | 2019-2023 | Subvenite, Lamotrigine |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.47 | 2025 | Rejoyn |
| Validus Pharmaceuticals LLC | $26.95 | 2022 | |
| Mdd US Operations, LLC | $23.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.61 | 2020 | |
| Lilly USA, LLC | $17.49 | 2024 | Zepbound, Jardiance |
| Neuronetics, INC. | $17.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Hauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.